A systematic review of OCT and OCT angiography in retinal vasculitis.
OCT
OCT-Angiography
OCT-EDI
Optical coherence tomography
Retinal vasculitis
Uveitis
Journal
Journal of ophthalmic inflammation and infection
ISSN: 1869-5760
Titre abrégé: J Ophthalmic Inflamm Infect
Pays: Germany
ID NLM: 101553216
Informations de publication
Date de publication:
30 Jan 2023
30 Jan 2023
Historique:
received:
19
09
2022
accepted:
21
01
2023
entrez:
30
1
2023
pubmed:
31
1
2023
medline:
31
1
2023
Statut:
epublish
Résumé
Retinal vasculitis is a component of uveitis for which the Standardisation of Uveitis Nomenclature (SUN) working group has no standard diagnostic criteria or severity grading. Fluorescein angiography is the gold standard test to assess retinal vasculitis, but is invasive and time-consuming. Optical coherence tomography (OCT) provides non-invasive detailed imaging of retinal structures and abnormalities, including blood vessel architecture and flow with OCT angiography (OCT-A). However, use of OCT in retinal vasculitis beyond assessing macular oedema, is not well established. We conducted a systematic review to understand the features of retinal vasculitis in OCT, Enhanced-depth imaging OCT (OCT-EDI) and OCT-A imaging. The systematic search was done in March 2022 and updated in January 2023, through PubMed, EMBASE and the Web of Science database for studies related to OCT, OCT-EDI and OCT-A findings and retinal vasculitis. Bias assessment was assessed using JBI Critical Appraisal Checklist, and any findings associated with retinal vasculitis were extracted by qualitative analysis. We identified 20 studies, including 8 articles on OCT, 6 on OCT-EDI and 6 on OCT-A. The studies included analytical retrospective studies, case-series, and a case-control study. Five OCT studies reported secondary complications could be detected, and four reported retinal thickness alteration in retinal vasculitis. Five studies explored choroidal thickness alteration in OCT-EDI, and four explored capillary density alterations in retinal vasculitis using OCT-A. The heterogeneity in the studies' analysis and design precluded a meta-analysis. There were no clear OCT, OCT-EDI or OCT-A findings that demonstrated potential to supersede fluorescein angiography for assessing retinal vasculitis. Some signs of macular structural effects secondary to retinal vasculitis may help prognostication for vision. The OCT signs of inflamed retinal vessels and perivascular tissue is an unexplored area.
Sections du résumé
BACKGROUND
BACKGROUND
Retinal vasculitis is a component of uveitis for which the Standardisation of Uveitis Nomenclature (SUN) working group has no standard diagnostic criteria or severity grading. Fluorescein angiography is the gold standard test to assess retinal vasculitis, but is invasive and time-consuming. Optical coherence tomography (OCT) provides non-invasive detailed imaging of retinal structures and abnormalities, including blood vessel architecture and flow with OCT angiography (OCT-A). However, use of OCT in retinal vasculitis beyond assessing macular oedema, is not well established. We conducted a systematic review to understand the features of retinal vasculitis in OCT, Enhanced-depth imaging OCT (OCT-EDI) and OCT-A imaging.
METHODS
METHODS
The systematic search was done in March 2022 and updated in January 2023, through PubMed, EMBASE and the Web of Science database for studies related to OCT, OCT-EDI and OCT-A findings and retinal vasculitis. Bias assessment was assessed using JBI Critical Appraisal Checklist, and any findings associated with retinal vasculitis were extracted by qualitative analysis.
RESULTS
RESULTS
We identified 20 studies, including 8 articles on OCT, 6 on OCT-EDI and 6 on OCT-A. The studies included analytical retrospective studies, case-series, and a case-control study. Five OCT studies reported secondary complications could be detected, and four reported retinal thickness alteration in retinal vasculitis. Five studies explored choroidal thickness alteration in OCT-EDI, and four explored capillary density alterations in retinal vasculitis using OCT-A. The heterogeneity in the studies' analysis and design precluded a meta-analysis.
DISCUSSION
CONCLUSIONS
There were no clear OCT, OCT-EDI or OCT-A findings that demonstrated potential to supersede fluorescein angiography for assessing retinal vasculitis. Some signs of macular structural effects secondary to retinal vasculitis may help prognostication for vision. The OCT signs of inflamed retinal vessels and perivascular tissue is an unexplored area.
Identifiants
pubmed: 36715778
doi: 10.1186/s12348-023-00327-4
pii: 10.1186/s12348-023-00327-4
pmc: PMC9886715
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1Informations de copyright
© 2023. The Author(s).
Références
Am J Ophthalmol. 2017 May;177:206-212
pubmed: 28263735
PLoS One. 2018 Dec 11;13(12):e0208254
pubmed: 30533014
Retina. 2011 Sep;31(8):1609-19
pubmed: 21844839
Ocul Immunol Inflamm. 2020 May 18;28(4):606-612
pubmed: 31560571
Retina. 2022 Oct 1;42(10):1897-1908
pubmed: 35976249
Indian J Ophthalmol. 2018 Mar;66(3):433-438
pubmed: 29480258
Int J Retina Vitreous. 2018 Apr 16;4:15
pubmed: 29692926
Retina. 2016 Oct;36(10):1979-85
pubmed: 26991648
Br J Ophthalmol. 2014 Jun;98(6):785-9
pubmed: 24511084
Ocul Immunol Inflamm. 2017 Jun;25(3):424-433
pubmed: 28696172
Acta Ophthalmol. 2019 Aug;97(5):e785-e791
pubmed: 30729711
Am J Ophthalmol. 2005 Sep;140(3):509-16
pubmed: 16196117
Eur J Ophthalmol. 2021 Mar;31(2):482-490
pubmed: 32019337
Ther Adv Ophthalmol. 2021 Jun 28;13:25158414211022875
pubmed: 34263133
Ocul Immunol Inflamm. 2017 Feb;25(1):7-19
pubmed: 27541278
Am J Ophthalmol. 2017 Jul;179:171-178
pubmed: 28501390
Sci Rep. 2021 Oct 8;11(1):20037
pubmed: 34625624
Retina. 2019 Jan;39(1):79-87
pubmed: 29135803
J Ophthalmic Inflamm Infect. 2013 Feb 11;3(1):30
pubmed: 23514542
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT591-9
pubmed: 27599125
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Br J Ophthalmol. 2007 Dec;91(12):1680-5
pubmed: 17591668
Graefes Arch Clin Exp Ophthalmol. 2014 Dec;252(12):1871-83
pubmed: 25363655
Surv Ophthalmol. 2021 Jan - Feb;66(1):54-67
pubmed: 32450158
Mil Med Res. 2020 Feb 29;7(1):7
pubmed: 32111253
Br J Ophthalmol. 2019 Sep;103(9):1289-1295
pubmed: 30538102
Retina. 2015 Dec;35(12):2633-40
pubmed: 26035402
Ocul Immunol Inflamm. 2020 May 18;28(4):589-600
pubmed: 31560572
Curr Opin Ophthalmol. 2003 Dec;14(6):413-9
pubmed: 14615648
Prog Retin Eye Res. 2020 Mar;75:100797
pubmed: 31513851
Acta Ophthalmol. 2016 Dec;94(8):815-823
pubmed: 27230297
Ocul Immunol Inflamm. 2021 Feb 17;29(2):346-351
pubmed: 31714872
Ther Adv Ophthalmol. 2021 Dec 6;13:25158414211059244
pubmed: 34901748
Ocul Immunol Inflamm. 2023 Jan;31(1):97-104
pubmed: 34644223
Br J Ophthalmol. 2018 Jun;102(6):815-820
pubmed: 28844053
JAMA Ophthalmol. 2014 Aug;132(8):929-35
pubmed: 24831429
Ocul Immunol Inflamm. 2019;27(3):383-388
pubmed: 30207804
Retina. 2017 Jan;37(1):112-117
pubmed: 27491042
Am J Ophthalmol. 2007 Dec;144(6):818-828
pubmed: 17949671
J Clin Med. 2022 Apr 30;11(9):
pubmed: 35566655
Sci Rep. 2019 Jun 13;9(1):8612
pubmed: 31197217
Retina. 2018 Apr;38(4):828-840
pubmed: 28272284
Int Ophthalmol. 2010 Oct;30(5):539-52
pubmed: 18795232
Int J Evid Based Healthc. 2015 Sep;13(3):147-53
pubmed: 26317388
Br J Ophthalmol. 2011 Sep;95(9):1245-50
pubmed: 21183514
Ophthalmol Retina. 2021 Dec;5(12):1226-1234
pubmed: 33610835
Acta Ophthalmol. 2013 Feb;91(1):48-51
pubmed: 21854554
Curr Opin Rheumatol. 2016 May;28(3):228-35
pubmed: 26945335
Sci Rep. 2022 Jan 14;12(1):752
pubmed: 35031636
Surv Ophthalmol. 2021 Jul-Aug;66(4):653-667
pubmed: 33412171
Clin Exp Ophthalmol. 2019 Apr;47(3):357-371
pubmed: 30719788
Prog Retin Eye Res. 2018 May;64:1-55
pubmed: 29229445
Int Ophthalmol. 2019 Oct;39(10):2391-2399
pubmed: 30710254
Int Ophthalmol. 2014 Apr;34(2):401-35
pubmed: 23835664
Am J Ophthalmol. 2015 Jun;159(6):1161-1168.e1
pubmed: 25709064